Eli Lilly and Company (NYSE:LLY ... from performance as recent GLP-1 revenue results missed heightened expectations. We view ...
As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...